NuVasive Gets FDA’s 510(k) Clearance for Expanded Use for Its Attrax Putty

NuVasive has received the FDA’s 510(k) clearance for expanded indications for its Attrax Putty for spine surgery.

The putty is a synthetic, bioactive and osteoconductive bone-void filler designed to promote bone fusion. The biomaterial features a surface microarchitecture that improves bone formation without the need for added cells or growth factors.

The synthetic biologic product is indicated for interbody fusions of the thoracolumbar spine — the transitional zone between the thoracic cage and the mobile lumbar spine.